Description: Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany.
Home Page: mainzbiomed.com
Robert Koch Strasse 50
Mainz,
55129
Germany
Phone:
49 6131 554 2860
Officers
| Name | Title |
|---|---|
| Mr. Guido Baechler | CEO & Executive Director |
| Mr. William J. Caragol CPA | Chief Financial Officer |
| Dr. Christopher Von Torne P.M.P., Ph.D. | Chief Operating Officer |
| Dr. Frank Krieg-Schneider | Chief Technology Officer |
| Dr. Moritz Eidens Ph.D. | Chief Science Officer & Executive Director |
| Stefan Erlach | Head of Human Resources |
| Mr. Philipp Freese | Chief Business Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7217 |
| Price-to-Sales TTM: | 0.4367 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 65 |